Zytiga Tablet
Product Images NDC 57894-150

7 FDA label images from Janssen Biotech, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Zytiga (NDC 57894-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Biotech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zytiga 01)

Chemical Structure (Zytiga 01)
Chemical structure diagram of abiraterone acetate, the active ingredient in Zytiga tablets. The structure shows its steroidal backbone with acetate and pyridine functional groups distinctly illustrated.*
FDA Label Image

Figure 1 (Zytiga 02)

Figure 1 (Zytiga 02)
A Kaplan-Meier survival curve comparing the percentage survival over time in months between Zytiga (Abiraterone acetate) and placebo groups. The graph shows time to death in months on the x-axis and percent survival on the y-axis, with Zytiga and placebo represented by separate lines.*
FDA Label Image

Figure 2 (Zytiga 03)

Figure 2 (Zytiga 03)
A Kaplan-Meier survival curve graph depicting the percentage of subjects without death over time in months from randomization for Zytiga and Placebo groups. The x-axis shows time in months, and the y-axis shows the percentage of subjects without death. Two lines represent survival rates for Zytiga and Placebo, with Zytiga showing higher survival over the study period.*
FDA Label Image

Figure 3 (Zytiga 04)

Figure 3 (Zytiga 04)
A Kaplan-Meier survival curve chart comparing the percentage of subjects without radiographic progression or death over time (months from randomization) between Zytiga and placebo groups. The chart shows two stepwise curves, with Zytiga's curve consistently above the placebo's, indicating a higher percentage of progression-free subjects over an 18-month period.*
FDA Label Image

Figure 4 (Zytiga 05)

Figure 4 (Zytiga 05)
A Kaplan-Meier survival curve chart showing the percentage survival of subjects without death over months from randomization. It compares two groups: Zytiga and Placebo. The survival rate for Zytiga remains higher than Placebo throughout the study period, with data points for the number of subjects at risk at specified time intervals.*
FDA Label Image

250 mg (Zytiga Tablets 250 mg 120 Tabs Label 783371 Edms Rim 397388 2.0 Crop)

250 mg (Zytiga Tablets 250 mg 120 Tabs Label 783371 Edms Rim 397388 2.0 Crop)
Packaging label for Zytiga 250 mg tablets (abiraterone acetate) manufactured by Janssen Biotech, Inc. The label states each tablet contains 250 mg of abiraterone acetate. It includes storage instructions, a warning for women who are or may be pregnant, and directions to swallow whole without crushing or chewing. The package contains 120 tablets.*
FDA Label Image

500 mg (Zytiga Tablets 500 mg 60 Tabs Bottle Label 783372 Edms Eri 122808989 7.0 Crop)

500 mg (Zytiga Tablets 500 mg 60 Tabs Bottle Label 783372 Edms Eri 122808989 7.0 Crop)
Label for Zytiga 500 mg (abiraterone acetate) film-coated tablets. The label states the strength as 500 mg per tablet and specifies a package size of 60 tablets. It includes storage instructions, manufacturer Janssen Biotech, Inc., and a note that the package is child-resistant. The Johnson & Johnson logo appears in red.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.